甲基3-氨基-6-氟-1-苯并噻吩-2-羧酸酯 | 142363-99-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 甲基3-氨基-6-氟-1-苯并噻吩-2-羧酸酯
• 英文名称: methyl 3-amino-6-fluorobenzothiophene-2-carboxylate
• 英文别名: methyl-6-fluoro-3-aminobenzo[b]thiophene-2-carboxylate；2-carbomethoxy-3-amino-6-fluoro-benzo[b]thiophene；Methyl 3-amino-6-fluoro-1-benzothiophene-2-carboxylate
• CAS: 142363-99-3
• 化学式: C₁₀H₈FNO₂S
• 分子量: 225.243
• InChiKey: QPPUQPQQFRVVOD-UHFFFAOYSA-N

物化性质

• 沸点：
  366.5±37.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲基3-氨基-6-氟-1-苯并噻吩-2-羧酸酯 在 N-甲基哌嗪 作用下， 以 various solvent(s) 为溶剂， 反应 16.0h， 生成 1-(6-fluorobenzo[b]thiophen-3-yl)-piperazine
  参考文献：
  名称：

  与[3- [4- [4-（6-氟代苯并[b]噻吩-3-基] -1-哌嗪基]丁基] -2,5]相关的一系列新型（哌嗪基丁基）噻唑烷酮类抗精神病药的结构活性关系， 5-三甲基-4-噻唑烷酮马来酸酯。

  摘要：

  HP-236（3- [4- [4-（6-氟苯并[b]噻吩-3-基）-1-哌嗪基]丁基] -2,5,5-三甲基-4-噻唑烷酮马来酸酯； P-9236） （54）显示了潜在的非典型抗精神病药活性的药理学特征。制备了与该化合物结构相关的一系列哌嗪基丁基丁基噻唑烷酮，并在体外评估了多巴胺D2和5-羟色胺5HT2和5HT1A受体的亲和力。在具有潜在抗精神病活性的动物模型中对化合物进行了体内检查，并在预测锥体束外副作用（EPS）责任的模型中进行了筛选。描述了这些化合物的合成，其结构-活性关系的详细信息以及新的先导化合物50的发现，以及化合物50和54的分布图的进一步发展。

  DOI：

  10.1021/jm960268u
• 作为产物：
  描述：

  methyl [(2-cyano-5-fluorophenyl)sulfanyl]acetate 在 18-冠醚-6 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以382 g的产率得到甲基3-氨基-6-氟-1-苯并噻吩-2-羧酸酯
  参考文献：
  名称：

  US2023/167080

  摘要：

  公开号：

文献信息

• Benzoisothiazole- and benziosoxazole-3-carboxamides
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05143923A1

  公开（公告）日：1992-09-01

  Novel benzisothiazole- and benzisoxazole-3-carboxamides, processes and intermediates for the preparation thereof, and methods of treating psychoses utilizing compounds and compositions thereof are disclosed.

  揭示了新型苯并异噻唑基和苯并异噁唑基-3-甲酰胺，其制备过程和中间体，以及利用这些化合物和组合物治疗精神病的方法。
• Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands
  申请人：——

  公开号：US20030229066A1

  公开（公告）日：2003-12-11

  The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  该发明涉及对多巴胺D3受体显示选择性结合的杂环取代脲衍生物。另一方面，该发明涉及一种用于治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，患者需要接受此类治疗，包括向受试者施用所述化合物的治疗有效量以缓解此类疾病。可以用这些化合物治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑障碍、睡眠障碍、昼夜节律障碍和情绪障碍。该发明还涉及所述化合物的制备过程以及将其作为多巴胺D3受体成像剂的方法。
• [EN] HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS<br/>[FR] DERIVES DE CARBONYLE SUBSTITUES HETEROCYCLIQUES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR DE LA DOPAMINE D3
  申请人：AVENTIS PHARMA INC

  公开号：WO2002066446A1

  公开（公告）日：2002-08-29

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson s Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington s Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D¿3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地结合多巴胺D3受体。另一方面，本发明涉及一种用于治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的过程，以及将所述化合物用作多巴胺D3受体成像剂的方法。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20050107389A1

  公开（公告）日：2005-05-19

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其表现出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物作为多巴胺D3受体成像剂的方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor
  申请人：Aventis Pharmaceutical Inc.

  公开号：US20040220173A1

  公开（公告）日：2004-11-04

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，该衍生物显示出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者给予所述化合物的治疗有效量以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程以及将其作为多巴胺D3受体成像剂的方法。